Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of LY03003 in Advanced Parkinson's Disease
NCT04630860Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Jul 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Rotigotine extended-release microspheres in Parkinson's disease (PD) (3 arms), sponsored by Luye Pharma Group. Primary endpoints: Safety evaluation at Day 50 and Maximum Plasma Concentration at Steady State at Day 50. Started Jul 2020; status: completed.
02
Drugs
Rotigotine extended-release microspheres
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04630860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630860.